about
Epigenetic control of HIV-1 post integration latency: implications for therapyHistone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi babyPreventing and managing HIV infection in infants, children, and adolescents in the United States.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells.Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities.Select host restriction factors are associated with HIV persistence during antiretroviral therapy.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.Human Galectin-9 Is a Potent Mediator of HIV Transcription and ReactivationActivation and lysis of human CD4 cells latently infected with HIV-1The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells.Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators.Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.Gene therapy targeting HIV entry.Eradication of HIV and Cure of AIDS, Now and How?Reactivation of latent HIV: do all roads go through P-TEFb?Role of Fc-mediated antibody function in protective immunity against HIV-1.The dawn of active genetics.Sequence-specific alterations of epitope production by HIV protease inhibitors.Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy ApproachGenome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection.HIV Protease Inhibitor-Induced Cathepsin Modulation Alters Antigen Processing and Cross-PresentationInhibitory Effect of 2,3,5,6-Tetrafluoro-4-[4-(aryl)-1H-1,2,3-triazol-1-yl]benzenesulfonamide Derivatives on HIV Reverse Transcriptase Associated RNase H Activities.Alpha-helicoidal HEAT-like Repeat Proteins (αRep) Selected as Interactors of HIV-1 Nucleocapsid Negatively Interfere with Viral Genome Packaging and Virus Maturation.Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency.CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency.Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.
P2860
Q26781191-45938A1F-B527-4EAB-8175-7F99E325DF50Q28537694-7B9D6A36-4AB7-44E5-B385-DA6205A26CECQ33557037-B02E95EA-25A0-40AE-8D54-B38CD5C52E25Q33808736-9080A428-9E97-4CBB-A96F-AB7BD621B394Q34180174-92EF51D3-29AA-4BB6-BF54-4F10425A1E7BQ34561884-208B1B9F-ABBA-4BF1-8CEB-8A1E69F7EFEBQ35013490-DE0DE901-B121-4EAB-B315-D48BBBBBE160Q35271996-24CE362D-7016-4781-97E3-6EADCC69BFB0Q35833324-A5D2ABA3-8D68-4527-885B-1B0A1DFAB57FQ35973520-4164B8DA-8245-41E7-8D0C-7D17A14B5A64Q36037844-82146379-310F-41C9-B05A-6DAD7981FBE2Q36250921-824ED4BC-2513-4064-9B41-01B2D1FC97C0Q36302615-CA039F7B-298E-4E69-B4F4-CA8F292ACD55Q36361960-53201AFC-CDEF-46CE-AD6D-0C7B67DA73F1Q36435381-73D47E0B-BEBC-4192-9FDB-22398FE7185DQ36644877-98A7D93B-B1C3-404D-A670-D6AE3B8418CCQ37034469-91493496-4734-486D-89FE-83AC2D4CD626Q37383798-E45DE670-BCDD-4832-B055-B2CAE3ADA9C9Q37429714-CAAF959B-ABFD-4A70-A8C7-5C73507E4771Q37673157-1EDCE9AB-4076-4D0D-9323-180291004B0CQ38154888-AE9743E1-D2B8-49A2-B123-AC8C0FBDD965Q38177273-89F89026-0B54-444B-8C56-BE4A68E7D309Q38213061-771948A5-8C1A-4314-A88B-86B2145A6D08Q38667483-201EB5B9-06D5-4624-930B-15F258CBF31BQ38710071-97C79544-6F6F-4B30-B86B-A60EBEB0A52EQ38777152-A8DE082E-E073-46B3-A250-D73D4F527E8EQ40042102-94D2EA85-6B29-4982-95EF-1EF75247FDB4Q40743173-EC691CF3-BDB5-417E-A18B-0985830281CDQ40953028-3CFC4030-2060-4678-AFC4-117805E9F133Q45324180-7A85814A-B4A2-44BD-A898-05E017701DF6Q46971270-D4AA551E-0F1E-4C20-A027-7F9D62545CFEQ47120827-ABBAB336-2A39-4304-9132-A7CCC10236B1Q47553089-69343C04-339B-4DE1-87E0-5C466ADF74B6Q47563715-C4E0385D-7A9A-4C87-947B-BC5474AA9D9AQ52606459-AD34EDD2-72B7-4E2B-B76E-A5FB5F4FF8D4
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
HIV-1 eradication strategies: design and assessment
@ast
HIV-1 eradication strategies: design and assessment
@en
HIV-1 eradication strategies: design and assessment
@nl
type
label
HIV-1 eradication strategies: design and assessment
@ast
HIV-1 eradication strategies: design and assessment
@en
HIV-1 eradication strategies: design and assessment
@nl
prefLabel
HIV-1 eradication strategies: design and assessment
@ast
HIV-1 eradication strategies: design and assessment
@en
HIV-1 eradication strategies: design and assessment
@nl
P2860
P3181
P1476
HIV-1 eradication strategies: design and assessment
@en
P2093
Janet D. Siliciano
P2860
P304
P3181
P356
10.1097/COH.0B013E328361EACA
P407
P577
2013-07-01T00:00:00Z